Catecholamines Drugs Market - 2023-2030
Description
MARKET SIZE AND OVERVIEW
Global Catecholamines Drugs Market reached US$ YY million in 2022 and is expected to reach US$ YY million by 2030, growing with a CAGR of YY % during the forecast period 2023-2030.
Catecholamines are hormones made by your adrenal glands, two small glands located above your kidneys. These hormones are released into the body in response to physical or emotional stress. The main types of catecholamines are dopamine, norepinephrine, and epinephrine. Epinephrine is also known as adrenaline. Catecholamine tests measure the amount of these hormones in your urine or blood. Higher than normal levels of dopamine, norepinephrine, and/or epinephrine can be a sign of a serious health condition.
After an external stimulus triggers the body’s stress response, the pituitary-adrenal axis and sympathetic division of the autonomic nervous system are activated. Glucocorticoid production increases in the adrenal cortex and acetylcholine (Ach) is released from sympathetic splanchnic nerves. ACH binds to nicotinic receptors located on the membrane of chromaffin cells in the adrenal medulla.
MARKET SCOPE
Metrics Details
CAGR YY%
Size Available for Years 2021-2030
Forecast Period 2023-2030
Data Availability Value (US$)
Segments Covered Type, Drug Type, Route of Administration, Indication, Distribution Channel
Regions Covered North America, Europe, Asia-Pacific, South America and Middle East & Africa
Largest Region North America
Fastest Growing Region Asia-Pacific
Report Insights Covered Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis and Other key Insights.
For more details of the report- Request for sample (https://www.datamintelligence.com/research-report/catecholamines-drugs-market)
MARKET DYNAMICS: DRIVERS AND RESTRAINTS
ADVANCEMENTS IN DRUG DELIVERY SYSTEMS
Technological advancements in drug delivery systems are one of the significant key factor that helps the market during the forecast period. These advancements have the potential to improve the administration, efficacy, and safety of catecholamine medications.
The development of advanced infusion pumps and devices has revolutionized the delivery of catecholamines. These devices allow for precise control over infusion rates, enabling healthcare professionals to administer catecholamines in a controlled and consistent manner.
Advanced infusion pumps also offer features such as programmable dosing, multiple infusion modes, and integration with patient monitoring systems, enhancing the overall safety and efficiency of catecholamine therapy.
Needle-free delivery devices for catecholamine administration, such as jet injectors and needle-free injectors (https://www.datamintelligence.com/research-report/needle-free-injection-market), are being investigated as alternatives to standard needle-based injections. These systems employ pressure or gas to force drugs into the skin, removing the need for needles and lowering pain and anxiety. Needle-free administration devices may increase patient comfort, convenience, and drug adherence.
Furthermore, the catecholamines market is also driven by various factors like, a rise in the prevalence of cardiovascular diseases, a rise in the geriatric population, a rise in the prevalence of chronic disorders and others will help the market to grow during the forecast period.
MARKET DYNAMICS: RESTRAINT
The presence of side effects and adverse reactions is one of the restraints for the catecholamines market. Catecholamines such as norepinephrine and epinephrine can induce a range of cardiovascular effects, including elevated heart rate, increased blood pressure, and arrhythmias. These physiological responses can lead to significant complications, particularly in individuals with preexisting cardiovascular conditions or certain sensitivities, thereby hampering market growth.
MARKET SEGMENTATION
The global catecholamines drugs market is segmented based on type, drug type, route of administration, indication, distribution channel and region.
THE DOPAMINE SEGMENT FROM THE DRUG TYPE SEGMENT ACCOUNTED FOR APPROXIMATELY 43.7% OF THE CATECHOLAMINE DRUGS MARKET SHARE
The dopamine segment from the drug type segment accounted for approximately 43.7% and it is expected to be dominated during the forecast period. Dopamine is a member of a class of molecules called catecholamines, which serve as neurotransmitters and hormones. In the brain, dopamine serves as a neurotransmitter and is released from nerve cells to send signals to other nerves. Outside of the nervous system, it acts as a local chemical messenger in several parts of the body. Overall, dopamine plays an important role in the catecholamines market due to its fast onset of action and other variable factors which help the market to grow during the forecast period.
MARKET GEOGRAPHICAL SHARE
NORTH AMERICA ACCOUNTED FOR APPROXIMATELY 38.4% OF THE MARKET SHARE IN 2022
North America is estimated to hold about 38.4% of the total market share throughout the forecast period, owing to the factors like advanced healthcare infrastructure, FDA approvals and emphasis on emergency medical care. Also, North America's robust pharmaceutical industry and regulatory framework support the development, production, and availability of catecholamine medications, thereby escalating market growth. Furthermore, the high prevalence of chronic diseases, the ageing population, and increasing awareness of severe allergies further propel the demand for catecholamines in emergency and critical care scenarios.
For instance, in September 2023, Baxter International Inc., a global leader in sterile medication production and delivery, stated the U.S. Food and Drug Administration (FDA) approval and commercial launch of premix Norepinephrine Bitartrate in 5% Dextrose Injection (norepinephrine). Norepinephrine is indicated to raise blood pressure in adult patients with severe, acute hypotension (low blood pressure).
COVID-19 IMPACT ANALYSIS
The emergence of the COVID-19 pandemic had a negative impact on the catecholamines market. The widespread disruptions to healthcare systems, travel restrictions, and economic downturns have collectively led to a decrease in the demand for catecholamine-based pharmaceuticals. Also, due to the redirection of medical resources toward treating COVID-19 patients, non-essential medical procedures were postponed or cancelled, leading to a reduced demand for products that make use of catecholamines.
COMPETITIVE LANDSCAPE
The major global players in the market include Pfizer, Inc., Baxter International (https://pharmaceuticals.baxter.com/our-products/high-alert-ready-use-premix-medications), Viatris, Inc., Amneal Pharmaceuticals, Lexicare Pharma Pvt. Ltd., Armstrong Pharmaceuticals, Inc., Adamis Pharmaceuticals Corporation, Wellona Pharma, Teva Pharmaceuticals, Kaleo Inc and among others.
KEY DEVELOPMENTS
• In June 2023, Fresenius Kabi stated the availability in the United States of Vasopressin Injection, USP, a generic equivalent to Vasostrict. Fresenius Kabi Vasopressin Injection, USP is an approved treatment option for adults with vasodilatory shock and is available in a 20-units per 1 mL Single Dose Vial.
• In August 2021, Breckenridge Pharmaceutical, Inc. launched a norepinephrine bitartrate injection, USP (generic for Levophed), manufactured by Rafarm S.A. Breckenridge marketed the product in its label and offered 4 mg/4 mL (1 mg /mL) strength in cartons of 10 vials. This strategy helped the company to expand its product offering, thereby generating revenue from its sales.
WHY PURCHASE THE REPORT?
• To visualize the global catecholamines drugs market segmentation based on type, drug type, route of administration, indication, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of catecholamines drugs market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
THE GLOBAL CATECHOLAMINES DRUGS MARKET REPORT WOULD PROVIDE APPROXIMATELY 61 TABLES, 58 FIGURES AND 187 PAGES.
TARGET AUDIENCE 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies
Global Catecholamines Drugs Market reached US$ YY million in 2022 and is expected to reach US$ YY million by 2030, growing with a CAGR of YY % during the forecast period 2023-2030.
Catecholamines are hormones made by your adrenal glands, two small glands located above your kidneys. These hormones are released into the body in response to physical or emotional stress. The main types of catecholamines are dopamine, norepinephrine, and epinephrine. Epinephrine is also known as adrenaline. Catecholamine tests measure the amount of these hormones in your urine or blood. Higher than normal levels of dopamine, norepinephrine, and/or epinephrine can be a sign of a serious health condition.
After an external stimulus triggers the body’s stress response, the pituitary-adrenal axis and sympathetic division of the autonomic nervous system are activated. Glucocorticoid production increases in the adrenal cortex and acetylcholine (Ach) is released from sympathetic splanchnic nerves. ACH binds to nicotinic receptors located on the membrane of chromaffin cells in the adrenal medulla.
MARKET SCOPE
Metrics Details
CAGR YY%
Size Available for Years 2021-2030
Forecast Period 2023-2030
Data Availability Value (US$)
Segments Covered Type, Drug Type, Route of Administration, Indication, Distribution Channel
Regions Covered North America, Europe, Asia-Pacific, South America and Middle East & Africa
Largest Region North America
Fastest Growing Region Asia-Pacific
Report Insights Covered Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis and Other key Insights.
For more details of the report- Request for sample (https://www.datamintelligence.com/research-report/catecholamines-drugs-market)
MARKET DYNAMICS: DRIVERS AND RESTRAINTS
ADVANCEMENTS IN DRUG DELIVERY SYSTEMS
Technological advancements in drug delivery systems are one of the significant key factor that helps the market during the forecast period. These advancements have the potential to improve the administration, efficacy, and safety of catecholamine medications.
The development of advanced infusion pumps and devices has revolutionized the delivery of catecholamines. These devices allow for precise control over infusion rates, enabling healthcare professionals to administer catecholamines in a controlled and consistent manner.
Advanced infusion pumps also offer features such as programmable dosing, multiple infusion modes, and integration with patient monitoring systems, enhancing the overall safety and efficiency of catecholamine therapy.
Needle-free delivery devices for catecholamine administration, such as jet injectors and needle-free injectors (https://www.datamintelligence.com/research-report/needle-free-injection-market), are being investigated as alternatives to standard needle-based injections. These systems employ pressure or gas to force drugs into the skin, removing the need for needles and lowering pain and anxiety. Needle-free administration devices may increase patient comfort, convenience, and drug adherence.
Furthermore, the catecholamines market is also driven by various factors like, a rise in the prevalence of cardiovascular diseases, a rise in the geriatric population, a rise in the prevalence of chronic disorders and others will help the market to grow during the forecast period.
MARKET DYNAMICS: RESTRAINT
The presence of side effects and adverse reactions is one of the restraints for the catecholamines market. Catecholamines such as norepinephrine and epinephrine can induce a range of cardiovascular effects, including elevated heart rate, increased blood pressure, and arrhythmias. These physiological responses can lead to significant complications, particularly in individuals with preexisting cardiovascular conditions or certain sensitivities, thereby hampering market growth.
MARKET SEGMENTATION
The global catecholamines drugs market is segmented based on type, drug type, route of administration, indication, distribution channel and region.
THE DOPAMINE SEGMENT FROM THE DRUG TYPE SEGMENT ACCOUNTED FOR APPROXIMATELY 43.7% OF THE CATECHOLAMINE DRUGS MARKET SHARE
The dopamine segment from the drug type segment accounted for approximately 43.7% and it is expected to be dominated during the forecast period. Dopamine is a member of a class of molecules called catecholamines, which serve as neurotransmitters and hormones. In the brain, dopamine serves as a neurotransmitter and is released from nerve cells to send signals to other nerves. Outside of the nervous system, it acts as a local chemical messenger in several parts of the body. Overall, dopamine plays an important role in the catecholamines market due to its fast onset of action and other variable factors which help the market to grow during the forecast period.
MARKET GEOGRAPHICAL SHARE
NORTH AMERICA ACCOUNTED FOR APPROXIMATELY 38.4% OF THE MARKET SHARE IN 2022
North America is estimated to hold about 38.4% of the total market share throughout the forecast period, owing to the factors like advanced healthcare infrastructure, FDA approvals and emphasis on emergency medical care. Also, North America's robust pharmaceutical industry and regulatory framework support the development, production, and availability of catecholamine medications, thereby escalating market growth. Furthermore, the high prevalence of chronic diseases, the ageing population, and increasing awareness of severe allergies further propel the demand for catecholamines in emergency and critical care scenarios.
For instance, in September 2023, Baxter International Inc., a global leader in sterile medication production and delivery, stated the U.S. Food and Drug Administration (FDA) approval and commercial launch of premix Norepinephrine Bitartrate in 5% Dextrose Injection (norepinephrine). Norepinephrine is indicated to raise blood pressure in adult patients with severe, acute hypotension (low blood pressure).
COVID-19 IMPACT ANALYSIS
The emergence of the COVID-19 pandemic had a negative impact on the catecholamines market. The widespread disruptions to healthcare systems, travel restrictions, and economic downturns have collectively led to a decrease in the demand for catecholamine-based pharmaceuticals. Also, due to the redirection of medical resources toward treating COVID-19 patients, non-essential medical procedures were postponed or cancelled, leading to a reduced demand for products that make use of catecholamines.
COMPETITIVE LANDSCAPE
The major global players in the market include Pfizer, Inc., Baxter International (https://pharmaceuticals.baxter.com/our-products/high-alert-ready-use-premix-medications), Viatris, Inc., Amneal Pharmaceuticals, Lexicare Pharma Pvt. Ltd., Armstrong Pharmaceuticals, Inc., Adamis Pharmaceuticals Corporation, Wellona Pharma, Teva Pharmaceuticals, Kaleo Inc and among others.
KEY DEVELOPMENTS
• In June 2023, Fresenius Kabi stated the availability in the United States of Vasopressin Injection, USP, a generic equivalent to Vasostrict. Fresenius Kabi Vasopressin Injection, USP is an approved treatment option for adults with vasodilatory shock and is available in a 20-units per 1 mL Single Dose Vial.
• In August 2021, Breckenridge Pharmaceutical, Inc. launched a norepinephrine bitartrate injection, USP (generic for Levophed), manufactured by Rafarm S.A. Breckenridge marketed the product in its label and offered 4 mg/4 mL (1 mg /mL) strength in cartons of 10 vials. This strategy helped the company to expand its product offering, thereby generating revenue from its sales.
WHY PURCHASE THE REPORT?
• To visualize the global catecholamines drugs market segmentation based on type, drug type, route of administration, indication, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of catecholamines drugs market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
THE GLOBAL CATECHOLAMINES DRUGS MARKET REPORT WOULD PROVIDE APPROXIMATELY 61 TABLES, 58 FIGURES AND 187 PAGES.
TARGET AUDIENCE 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies
Table of Contents
180 Pages
- 1. Methodology and Scope
- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report
- 2. Definition and Overview
- 3. Executive Summary
- 3.1. Snippet by Type
- 3.2. Snippet by Drug Type
- 3.3. Snippet by Route of Administration
- 3.4. Snippet by Indication
- 3.5. Snippet by Distribution Channel
- 3.6. Snippet by Region
- 4. Market Dynamics
- 4.1. Impacting Factors
- 4.1.1. Drivers
- 4.1.1.1. Advancements in drug delivery systems
- 4.1.1.2. Rise in the prevalence of cardiovascular diseases
- 4.1.2. Restraints
- 4.1.2.1. Side effects associated with drugs
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis
- 5. Industry Analysis
- 5.1. Porter's Five Force Analysis
- 5.2. Supply Chain Analysis
- 5.3. Pricing Analysis
- 5.4. Regulatory Analysis
- 5.5. Pipeline Analysis
- 5.6. Unmet Needs
- 5.7. DMI Opinion
- 6. COVID-19 Analysis
- 6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID
- 6.1.2. Scenario During COVID
- 6.1.3. Scenario Post COVID
- 6.2. Pricing Dynamics Amid COVID-19
- 6.3. Demand-Supply Spectrum
- 6.4. Government Initiatives Related to the Market During Pandemic
- 6.5. Manufacturers Strategic Initiatives
- 6.6. Conclusion
- 7. By Type
- 7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 7.1.2. Market Attractiveness Index, By Type
- 7.2. Endogenous *
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.3. Synthetic
- 8. By Drug Type
- 8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
- 8.1.2. Market Attractiveness Index, By Drug Type
- 8.2. Dopamine *
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.3. Norepinephrine
- 8.4. Epinephrine
- 9. By Route of Administration
- 9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 9.1.2. Market Attractiveness Index, By Route of Administration
- 9.2. Intravenous*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 9.3. Intramuscularly
- 9.4. Inhalation
- 9.5. Others
- 10. By Indication
- 10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
- 10.1.2. Market Attractiveness Index, By Indication
- 10.2. Anaphylaxis *
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 10.3. Cardiac Arrest
- 10.4. Acute Asthma
- 10.5. Shock
- 10.6. Hypertension
- 10.7. Others
- 11. By Distribution Channel
- 11.1. Introduction
- 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 11.1.2. Market Attractiveness Index, By Distribution Channel
- 11.2. Hospital Pharmacies *
- 11.2.1. Introduction
- 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 11.3. Retail Pharmacies
- 11.4. Online Pharmacies
- 12. By Region
- 12.1. Introduction
- 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 12.1.2. Market Attractiveness Index, By Region
- 12.2. North America
- 12.2.1. Introduction
- 12.2.2. Key Region-Specific Dynamics
- 12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
- 12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
- 12.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 12.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 12.2.8.1. U.S.
- 12.2.8.2. Canada
- 12.2.8.3. Mexico
- 12.3. Europe
- 12.3.1. Introduction
- 12.3.2. Key Region-Specific Dynamics
- 12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
- 12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
- 12.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 12.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 12.3.8.1. Germany
- 12.3.8.2. UK
- 12.3.8.3. France
- 12.3.8.4. Italy
- 12.3.8.5. Spain
- 12.3.8.6. Rest of Europe
- 12.4. South America
- 12.4.1. Introduction
- 12.4.2. Key Region-Specific Dynamics
- 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
- 12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
- 12.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 12.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 12.4.8.1. Brazil
- 12.4.8.2. Argentina
- 12.4.8.3. Rest of South America
- 12.5. Asia-Pacific
- 12.5.1. Introduction
- 12.5.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
- 12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
- 12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 12.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 12.5.7.1. China
- 12.5.7.2. India
- 12.5.7.3. Japan
- 12.5.7.4. Australia
- 12.5.7.5. Rest of Asia-Pacific
- 12.6. Middle East and Africa
- 12.6.1. Introduction
- 12.6.2. Key Region-Specific Dynamics
- 12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
- 12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 12.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
- 12.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 13. Competitive Landscape
- 13.1. Competitive Scenario
- 13.2. Market Positioning/Share Analysis
- 13.3. Mergers and Acquisitions Analysis
- 14. Company Profiles
- 14.1. Pfizer, Inc.*
- 14.1.1. Company Overview
- 14.1.2. Product Portfolio and Description
- 14.1.3. Financial Overview
- 14.1.4. Key Developments
- 14.2. Baxter International
- 14.3. Viatris, Inc
- 14.4. Amneal Pharmaceuticals
- 14.5. Lexicare Pharma Pvt. Ltd.
- 14.6. Armstrong Pharmaceuticals, Inc.
- 14.7. Adamis Pharmaceuticals Corporation
- 14.8. Wellona Pharma
- 14.9. Teva Pharmaceuticals
- 14.10. Kaleo Inc (*LIST NOT EXHAUSTIVE)
- 15. Appendix
- 15.1. About Us and Services
- 15.2. Contact Us
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
